TAM November/December 2023 CME Posttest
Continuing Medical Education Posttest
The following Topics in Antiviral Medicine™ issue offers continuing medical education (CME) credit:
November/December 2023, Volume 31, Issue 5
Overview
- CME Credit Available: 3.0 AMA PRA Category 1 Credits™
- Release Date: December 5, 2023
- Expiration Date: December 5, 2024
To complete the activity, read each article and successfully complete the posttest and evaluation form, which will help us evaluate this activity and plan future activities. Your responses will not affect your CME credit.
Learning Objectives
On completion of this activity, which contains 3 articles, the learner will be better able to:
- Outline the history of antibiotic prophylaxis for sexually transmitted infections, and the rationale, current evidence, and future directions for doxycyline postexposure prophylaxis (doxy-PEP)
- Describe the epidemiology and role of immune dysregulation in HIV-associated cardiovascular disease
- Utilize the latest recommendations from the US Department of Health and Human Services when providing guidance on infant feeding to their patients with HIV
Assessment of Needs
The IAS–USA offers this state-of-the-art activity as part of a nationwide CME effort for physicians in the evolving challenges of managing HIV and other viral infections.
Intended Audience
This enduring material is designed for physicians who are actively involved in the medical care of people with HIV and other viral infections. This activity is also relevant for other practitioners, including nurse practitioners, nurses, physician assistants, pharmacists, and others.
CME Information
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this enduring material for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This CME activity is offered from December 5, 2023 to December 5, 2024. Participants who successfully complete the activity posttest and submit the evaluation and registration forms are eligible to receive CME credit. Physicians (MDs, DOs, and international equivalents) may receive CME credit for completing this activity. Other health care practitioners will receive a certificate of participation.
Disclosure of Financial Interests
It is the policy of the IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities.
In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.
The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.”
IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenter and planners/reviewers is below and in the slides prior to the presentation of educational content.
Contributors
Dr Feinstein reported consulting for Abbott Laboratories. (Updated November 1, 2023)
Mr Avgousti reported no relevant financial relationships with ineligible companies. (Updated November 1, 2023)
Dr Cannon reported consulting for Roche Diagnostics. (Updated November 22, 2023)
Dr Celum reported serving as a scientific advisor to Merck, Gilead Sciences, and GSK/ViiV; grant support from Mayne Pharmaceuticals. (Updated November 22, 2023)
Dr Pollock reported consulting for Abbott Laboratories. (Updated November 22, 2023)
Dr Levison reported no relevant financial relationships with ineligible companies. (Updated November 22, 2023)
Planners/Reviewers
Reviewer 1 reported serving as a consultant or receiving advisor fees from Antiva, Assembly Biosciences, Generate Biomedicines, and IGM Biosciences, and receiving fees for participation in review activities, eg, data monitoring boards, statistical analysis, or endpoint adjudication committees with Gilead Sciences, Inc. (Updated November 30, 2023)
Reviewers 2 and 3 reported no relevant financial relationships with ineligible companies. (Updated November 30, 2023)
Topics in Antiviral Medicine Editorial Board
Dr Richman reported serving as a consultant or receiving advisor fees from Antiva, Assembly Biosciences, Generate Biomedicines, and IGM Biosciences, and receiving fees for participation in review activities, eg, data monitoring boards, statistical analysis, or endpoint adjudication committees with Gilead Sciences, Inc. (Updated November 30, 2023)
Dr Benson reported grants/grants pending awarded to her institution from DNAe Group Holdings, Ltd, Gilead Sciences, Inc., and Pfizer, Inc. (Updated June 30, 2023)
Dr Hirsch reported no relevant financial relationships with ineligible companies. (Updated November 30, 2023)
Grant Support
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors:
Independent educational grants for the 2023 Improving the Management of HIV Disease® CME program:
PLATINUM SUPPORTERS
Gilead Sciences, Inc
Merck & Co, Inc
ViiV Healthcare
BRONZE SUPPORTERS
Janssen Therapeutics
Theratechonologies Inc
Drug and Product Disclaimer
This activity may contain information about the investigational uses of drugs or products that are not approved by the US Food and Drug Administration. Please consult full prescribing information before using any medication or product mentioned in this activity.
The views and opinions expressed herein are those of faculty and do not necessarily represent the opinions or recommendations of IAS–USA.
Contact Information
If you have any questions about this activity, please contact the IAS–USA:
Email: journal@iasusa.org
Mail: 131 Steuart St, Ste 500, San Francisco, CA 94105
Phone: (415) 544-9400
By clicking the link below, I acknowledge that I have read these instructions and understand them.
You must log in to take the activity.
You must be logged in to access this course.